Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesca Musumeci

Showing results (21-30 of 58) with videos related to

Pageof 6
Sort By:
Molecules (Basel, Switzerland)|September 20, 2018
Optimization of Aminoimidazole Derivatives as Src Family Kinase InhibitorsCinzia Maria Francini, Francesca Musumeci, Anna Lucia Fallacara, et al.
Pharmaceutics|July 27, 2024
Exploring a New Generation of Pyrimidine and Pyridine Derivatives as Anti-Influenza Agents Targeting the Polymerase PA-PB1 Subunits InteractionIlaria Giacchello, Annarita Cianciusi, Chiara Bertagnin, et al.
Drug Metabolism and Pharmacokinetics|May 23, 2014
CYP-dependent metabolism of antitumor pyrazolo[3,4-d]pyrimidine derivatives is characterized by an oxidative dechlorination reactionClaudio Zamperini, Elena Dreassi, Giulia Vignaroli, et al.
Molecules (Basel, Switzerland)|April 27, 2024
Discovery of a Novel Chemo-Type for TAAR1 Agonism via Molecular ModelingGiancarlo Grossi, Naomi Scarano, Francesca Musumeci, et al.
Journal of Cellular Physiology|May 18, 2019
The small molecule SI113 hinders epithelial-to-mesenchymal transition and subverts cytoskeletal organization in human cancer cellsClaudia Abbruzzese, Silvia Matteoni, Michele Persico, et al.
Bioorganic & Medicinal Chemistry Letters|August 3, 2012
A combined targeted/phenotypic approach for the identification of new antiangiogenics agents active on a zebrafish model: from in silico screening to cyclodextrin formulationMarco Radi, Lasse Evensen, Elena Dreassi, et al.
Pharmaceutics|June 27, 2025
Evaluation of Antitumoral Activity in a 3D Cell Model of a Src Inhibitor Prodrug for Glioblastoma TreatmentLetizia Clementi, Federica Poggialini, Francesca Musumeci, et al.
Pharmaceuticals (Basel, Switzerland)|July 29, 2023
Identification and Biological Characterization of the Pyrazolo[3,4-<i>d</i>]pyrimidine Derivative SI388 Active as Src InhibitorClaudia Contadini, Claudia Cirotti, Anna Carbone, et al.
ACS Medicinal Chemistry Letters|May 22, 2020
Development of Pyrazolo[3,4-<i>d</i>]pyrimidine Kinase Inhibitors as Potential Clinical Candidates for Glioblastoma MultiformeChiara Greco, Vincenzo Taresco, Amanda K Pearce, et al.
European Journal of Medicinal Chemistry|January 12, 2017
Identification of new pyrrolo[2,3-d]pyrimidines as Src tyrosine kinase inhibitors in vitro active against GlioblastomaFrancesca Musumeci, Anna Lucia Fallacara, Chiara Brullo, et al.
Pageof 6

Showing results (21-30 of 58) with videos related to

Sort By:
Pageof 6
Molecules (Basel, Switzerland)|September 20, 2018
Optimization of Aminoimidazole Derivatives as Src Family Kinase InhibitorsCinzia Maria Francini, Francesca Musumeci, Anna Lucia Fallacara, et al.
Pharmaceutics|July 27, 2024
Exploring a New Generation of Pyrimidine and Pyridine Derivatives as Anti-Influenza Agents Targeting the Polymerase PA-PB1 Subunits InteractionIlaria Giacchello, Annarita Cianciusi, Chiara Bertagnin, et al.
Drug Metabolism and Pharmacokinetics|May 23, 2014
CYP-dependent metabolism of antitumor pyrazolo[3,4-d]pyrimidine derivatives is characterized by an oxidative dechlorination reactionClaudio Zamperini, Elena Dreassi, Giulia Vignaroli, et al.
Molecules (Basel, Switzerland)|April 27, 2024
Discovery of a Novel Chemo-Type for TAAR1 Agonism via Molecular ModelingGiancarlo Grossi, Naomi Scarano, Francesca Musumeci, et al.
Journal of Cellular Physiology|May 18, 2019
The small molecule SI113 hinders epithelial-to-mesenchymal transition and subverts cytoskeletal organization in human cancer cellsClaudia Abbruzzese, Silvia Matteoni, Michele Persico, et al.
Bioorganic & Medicinal Chemistry Letters|August 3, 2012
A combined targeted/phenotypic approach for the identification of new antiangiogenics agents active on a zebrafish model: from in silico screening to cyclodextrin formulationMarco Radi, Lasse Evensen, Elena Dreassi, et al.
Pharmaceutics|June 27, 2025
Evaluation of Antitumoral Activity in a 3D Cell Model of a Src Inhibitor Prodrug for Glioblastoma TreatmentLetizia Clementi, Federica Poggialini, Francesca Musumeci, et al.
Pharmaceuticals (Basel, Switzerland)|July 29, 2023
Identification and Biological Characterization of the Pyrazolo[3,4-<i>d</i>]pyrimidine Derivative SI388 Active as Src InhibitorClaudia Contadini, Claudia Cirotti, Anna Carbone, et al.
ACS Medicinal Chemistry Letters|May 22, 2020
Development of Pyrazolo[3,4-<i>d</i>]pyrimidine Kinase Inhibitors as Potential Clinical Candidates for Glioblastoma MultiformeChiara Greco, Vincenzo Taresco, Amanda K Pearce, et al.
European Journal of Medicinal Chemistry|January 12, 2017
Identification of new pyrrolo[2,3-d]pyrimidines as Src tyrosine kinase inhibitors in vitro active against GlioblastomaFrancesca Musumeci, Anna Lucia Fallacara, Chiara Brullo, et al.
Pageof 6